# Inhibrx Biosciences, Inc.: overview INBX · Nasdaq · CIK 2007919 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31 Pages: [Overview](/companies/inbx.md) · [Financials](/companies/inbx/financials.md) · [Filings](/companies/inbx/filings.md) · [Insiders](/companies/inbx/insiders.md) Latest reported revenue: [$0](/filings/0002007919-26-000042.md) for Q2 FY2026, three months to 2026-06-30, from the 10-Q filed Aug 13, 2026 (XBRL us-gaap:Revenues, accession 0002007919-26-000042). ## Last eight quarters | Line item | Unit | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) | | --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | | Revenue | $m | [0.0](/filings/0002007919-25-000093.md) | [0.1 d](/filings/0002007919-26-000006.md) | [0.0](/filings/0002007919-25-000056.md) | [1.3](/filings/0002007919-26-000042.md) | [0.0](/filings/0002007919-25-000093.md) | [0.0 d](/filings/0002007919-26-000006.md) | not reported | [0.0](/filings/0002007919-26-000042.md) | | Gross margin | % | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | | Operating margin | % | not reported | [(49928.0%) d](/filings/0002007919-26-000006.md) | not reported | [(2106.8%)](/filings/0002007919-26-000042.md) | not reported | not reported | not reported | not reported | | Net margin | % | not reported | [(47865.0%) d](/filings/0002007919-26-000006.md) | not reported | [(2204.2%)](/filings/0002007919-26-000042.md) | not reported | not reported | not reported | not reported | | Diluted EPS | $ per share | [(2.84)](/filings/0002007919-25-000093.md) | not reported | [(2.80)](/filings/0002007919-26-000027.md) | [(1.85)](/filings/0002007919-26-000042.md) | [(2.28)](/filings/0002007919-25-000093.md) | not reported | [(2.15)](/filings/0002007919-26-000027.md) | [(2.34)](/filings/0002007919-26-000042.md) | | Free cash flow | $m | [(30.5) d](/filings/0002007919-25-000093.md) | [(43.7) d](/filings/0002007919-26-000006.md) | [(35.9)](/filings/0002007919-26-000027.md) | [(30.0) d](/filings/0002007919-26-000042.md) | [(33.8) d](/filings/0002007919-25-000093.md) | [(30.1) d](/filings/0002007919-26-000006.md) | [(38.0)](/filings/0002007919-26-000027.md) | [(29.9) d](/filings/0002007919-26-000042.md) | - Revenue. XBRL Revenue: us-gaap:Revenues. Derived values: 12-month figure less the 9-month figure. - Gross margin (gross profit / revenue). XBRL Revenue: us-gaap:Revenues. Derived values: 12-month figure less the 9-month figure. - Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:Revenues. Derived values: 12-month figure less the 9-month figure. - Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:Revenues. Derived values: 12-month figure less the 9-month figure. - Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted. - Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. Derived values: 9-month figure less the 6-month figure; 12-month figure less the 9-month figure; 6-month figure less the 3-month figure. ## Last five fiscal years | Line item | Unit | FY (2023-12-31) | FY2024 (2024-12-31) | FY2025 (2025-12-31) | | --- | --- | ---: | ---: | ---: | | Revenue | $m | [1.8](/filings/0002007919-25-000019.md) | [0.2](/filings/0002007919-26-000006.md) | [1.3](/filings/0002007919-26-000006.md) | | Gross margin | % | not reported | not reported | not reported | | Operating margin | % | [(12178.9%)](/filings/0002007919-25-000019.md) | [(165724.0%)](/filings/0002007919-26-000006.md) | [(10386.5%)](/filings/0002007919-26-000006.md) | | Net margin | % | [(13408.9%)](/filings/0002007919-25-000019.md) | [843786.0%](/filings/0002007919-26-000006.md) | [(10773.5%)](/filings/0002007919-26-000006.md) | | Diluted EPS | $ per share | [(20.48)](/filings/0002007919-25-000019.md) | [112.62](/filings/0002007919-26-000006.md) | [(9.04)](/filings/0002007919-26-000006.md) | | Free cash flow | $m | [(198)](/filings/0002007919-25-000019.md) | [(197)](/filings/0002007919-26-000006.md) | [(130)](/filings/0002007919-26-000006.md) | - Revenue. XBRL Revenue: us-gaap:Revenues. - Gross margin (gross profit / revenue). XBRL Revenue: us-gaap:Revenues. - Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:Revenues. - Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:Revenues. - Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted. - Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. Each value links to the filing it came from. d marks a derived value. A ratio is not reported when any input is missing. ## Insider purchases and sales The last 20 open-market transactions on Form 4 (codes P and S). Reported price is as stated on the form, not a market price. [All insider transactions](/companies/inbx/insiders.md) None in coverage. ## Funds that report holding it From each manager’s latest Form 13F, largest reported value first. Reported value is as filed: filing data, not a price. [All funds](/funds.md) | Fund | Quarter ended | Reported value | Shares | Put or call | Change on the quarter before | | --- | --- | ---: | ---: | --- | --- | | [MORGAN STANLEY](/funds/895421.md) | 2026-06-30 | $123.9m | 1,308,051 | | Added +44,973 | | [PERCEPTIVE ADVISORS LLC](/funds/1224962.md) | 2026-06-30 | $123.0m | 1,297,763 | | Reduced −144,944 | | [Sanofi](/funds/1121404.md) | 2026-06-30 | $109.7m | 1,157,926 | | Unchanged | | [VIKING GLOBAL INVESTORS LP](/funds/1103804.md) | 2026-06-30 | $106.5m | 1,123,929 | | Reduced −313,776 | | [HighTower Advisors, LLC](/funds/1462245.md) | 2026-06-30 | $82.5m | 870,551 | | Added +351 | | [BANK OF AMERICA CORP /DE/](/funds/70858.md) | 2026-06-30 | $79.7m | 841,141 | | Added +808,458 | | [BlackRock, Inc.](/funds/2012383.md) | 2026-06-30 | $78.3m | 825,972 | | Added +27,074 | | [Schonfeld Strategic Advisors LLC](/funds/1665241.md) | 2026-06-30 | $66.1m | 697,586 | | Added +442,759 | | [STATE STREET CORP](/funds/93751.md) | 2026-06-30 | $60.7m | 640,458 | | Added +89,613 | | [VANGUARD CAPITAL MANAGEMENT LLC](/funds/2100119.md) | 2026-06-30 | $46.7m | 492,477 | | Added +6,055 | ## Recent filings [All 151 filings](/companies/inbx/filings.md) | Filed | Accepted | Form | What it is | Accession | | --- | --- | --- | --- | --- | | 2026-09-28 | 21:03 ET | [8-K](/filings/0002007919-26-000050.md) | 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0002007919-26-000050 | | 2026-09-08 | 20:01 ET | [8-K](/filings/0002007919-26-000047.md) | 7.01 Regulation FD disclosure; 8.01 Other events; 9.01 Financial statements and exhibits | 0002007919-26-000047 | | 2026-08-13 | 20:10 ET | [8-K](/filings/0002007919-26-000044.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0002007919-26-000044 | | 2026-08-13 | 20:04 ET | [10-Q](/filings/0002007919-26-000042.md) | Quarterly report, period 2026-06-30 | 0002007919-26-000042 | | 2026-07-16 | 20:06 ET | [8-K](/filings/0002007919-26-000037.md) | 1.01 Entry into a material agreement; 2.03 New direct financial obligation; 3.02 Unregistered sale of equity; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0002007919-26-000037 | | 2026-06-15 | 20:06 ET | [8-K](/filings/0002007919-26-000033.md) | 7.01 Regulation FD disclosure; 8.01 Other events; 9.01 Financial statements and exhibits | 0002007919-26-000033 | | 2026-06-03 | 20:02 ET | [8-K](/filings/0002007919-26-000030.md) | 5.07 Shareholder vote results | 0002007919-26-000030 | | 2026-05-14 | 20:04 ET | [8-K](/filings/0002007919-26-000028.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0002007919-26-000028 | | 2026-05-14 | 20:02 ET | [10-Q](/filings/0002007919-26-000027.md) | Quarterly report, period 2026-03-31 | 0002007919-26-000027 | | 2026-05-11 | 20:02 ET | [8-K](/filings/0002007919-26-000020.md) | 7.01 Regulation FD disclosure; 8.01 Other events; 9.01 Financial statements and exhibits | 0002007919-26-000020 | ## Latest annual report [Form 10-K for the fiscal year ended Dec 31, 2025](/filings/0002007919-26-000006.md), filed Mar 19, 2026. ## Forecast league Q3 FY2026, the quarter ended 2026-09-30, is open for forecasts until the first results filing for it is accepted by EDGAR. Results are due by \[object Promise\]. [Forecast this quarter](/leagues/2026q3/targets/c2557056-a9c6-48e0-868d-0061d22e0770) ## About the filer - CIK: 2007919 - Tickers: INBX - Exchange: Nasdaq - SIC code: 2836 Biological Products, (No Diagnostic Substances) - State of incorporation: DE - Filer category:
Emerging growth company Source: SEC EDGAR, XBRL company facts, the filing index and Forms 4. Last ingested by Listed: Oct 24, 2026, 15:50 ET. No prices; not investment advice.